![]() Exhibit 99.1 |
![]() This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including, without limitation, our developmental stage and limited operating history, our ability to successfully develop products, rapid technological change in our markets, demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. Safe Harbor Statement |
![]() Arrowhead in the context of Inspiration vs Pragmatism Inspiration (Innovation) Pragmatism (Operations) Building Value follows a transition from focus on inspiration to pragmatism or operations • Natural transition for a maturing company Transition is underlined by the current economic environment Today’s primary focus |
![]() 2008 Was A Challenging Year • Implemented Revised Business Models for some subsidiaries • Lowered Cash Burn • Reduced Cost Structure • Consolidated of Management of Subsidiaries • CEOs of all subsidiaries are ARWR management |
![]() ![]() ![]() Reducing Cost Structure Jan ‘08 Mar ‘08 Jun ‘08 Sept ‘08 Dec ‘08 Mar ‘09 Further reductions in process Arrowhead and Subsidiaries’ Head Count |
![]() 2009 - We are Cautiously Optimistic • Further Reductions in Cost Structure • Extend Runway • Greater Focus on Nearer-term Unidym Opportunities • Calando Partnership Focus • Off-load burn • Retain upside potential • Generate License Revenues from Other Subsidiaries • Establish New and Further Leverage Existing Partnerships |
![]() 2008: • Sold high-end proprietary CNT materials commercially • Actively sampled CNT films with multiple major touch panel manufacturers • Strategic investment from Entegris • Customer that used CNTs for antistatic polymers • Development Agreement with Nippon Kayaku to integrate Unidym CNTs films into solar cells • Demonstrated world’s first active matrix LCD screen using CNT films • Samsung demonstrated first-ever CNT-based electrophoretic display using Unidym’s films • Samsung demonstrated first-ever CNT-based color 14.3’ format electrophoretic display using Unidym’s films • Demonstrated CNT-based analog resistive touch panel • Strategic investment from Tokyo Electron |
![]() 2009 Goals: • Continue to cut cost structure by focusing model • Leverage partnerships • Increase ARWR position in Unidym via stock transaction • Believe in the company • Significant downside potential in ARWR stock if Unidym fails, but only 51% of upside if Unidym succeeds • Exclusive supply contract for outsourced CNT production • Film channel partnership in Asia for touch panel market • Development agreement with a second major LCD manufacturer • Purchase order for film or ink for a commercial touch screen device |
![]() 2008: • Began Phase I clinical trial for CALAA-01 • We believe the first use of siRNA against cancer in humans • We believe the first clinical trial of systemic delivery of siRNA using a delivery vehicle • Launched Phase II clinical trial for IT-101 in Ovarian Cancer 2009 Goals: • Complete CALAA-01 Phase I • Thus far very well tolerated • Partner both the Cyclosert and RONDEL platforms • Limit future expenditures • Retain upside potential via possible milestone payments and royalties |
![]() 2008: • Partnership with Amberwave Systems • We believe they are well positioned and capitalized to bring the technology to market • Eliminates all costs going forward • Retains upside potential via milestone payments and royalties 2009 Goals: • Secure next milestone payment of $500k |
![]() 2008: • Explored use of large fullerene patent position for: • MRI contrast agent • Treatment of macular degeneration • Ceased operational expenditures to create license model • Enable ARWR to capture upside potential of fullerene- based therapeutics based on Tego IP via possible milestone payments and royalties • Assume no costs associated with clinical trials 2009 Goals: • Establish partnership/license agreement |
![]() 2008: • Launched to roll-up key IP for CNT-enabled supercapacitors • Leverage ARWR experience and knowledge in CNTs • Established corporate partnership for testing/development • Identified hybrid electric vehicles and inventory management on the power grid as key target markets • Began testing prototypes • Operates as a virtual company 2009 Goals: • No current operational costs • Compete for federal funds with corporate partner |
![]() Minority Positions |
![]() • Progress on focus areas of spinal cord regeneration and wound healing • New potential breakthrough in cartilage regeneration |
![]() • Progress on multistage drug delivery platform • Ferrari receives $7mm Innovator award to support Leonardo-based work • New potential breakthrough in cancer diagnostics Animal data suggest that the chips may be used to identify responders versus non-responders to cancer therapies |
![]() Capital Sources discussed at last earnings call 1. A single or series of partnerships for Calando 2. Direct investments into Calando from strategic and/or financial investors 3. Funded JDAs and partnerships for Unidym; 4. Revenue generated from Unidym sales; 5. License fees to Unidym; 6. Sale of Unidym’s bulk material business; 7. Direct investments into Unidym from strategic and/or financial investors 8. Sale of Tego; 9. Tego license fees; and 10. Continued scheduled pay-outs from the 2008 Aonex sale; |
![]() In process of partnering: • Expenses to decrease • Upside potential retained • Expenses to virtually zero • Upside potential retained • Reduced Costs • Anticipated increased ARWR position • Near commercialization • Potentially breakthrough technologies • High growth markets In Summary… |